EZ Cap™ BCMA CAR mRNA (5-moUTP)

B-cell maturation antigen (BCMA) is a transmembrane glycoprotein belonging to the tumor necrosis factor receptor superfamily, predominantly expressed on mature B lymphocytes and plasma cells. By binding to two ligands BAFF and APRIL, BCMA mediates essential signaling to support plasma cell survival, proliferation and differentiation. Highly overexpressed on multiple myeloma cells yet barely detectable in hematopoietic stem cells and most normal tissues, BCMA features favorable targeting safety and serves as a leading therapeutic target for multiple myeloma immunotherapy.

EZ Cap™ BCMA CAR mRNA (5-moUTP) encodes human BCMA-targeted chimeric antigen receptor (CAR). Upon cellular transfection, it efficiently expresses full-length CAR composed of anti-BCMA scFv, hinge region, transmembrane domain and intracellular signaling moiety. The engineered receptor specifically recognizes and binds surface BCMA on malignant cells to trigger immune cell activation and eliminate BCMA-positive tumor cells.

Key features:

Cap1 Structure: The mRNA incorporates a Cap1 analog at the 5' end, ensuring high translation initiation efficiency, improved stability, and reduced innate immune recognition, leading to stronger and more sustained luciferase expression.

Modified Nucleotides: It contains 5-methoxyuridine (5-moU) modified nucleotides, which decreases immunogenicity, enhances mRNA stability, and increases translational efficiency, resulting in more reliable and reproducible protein yield.

poly(A) tail: It contains an optimized poly(A) tail of approximately 100 nucleotides. This specific length is engineered to maximize transcript stability by resisting degradation and to synergize with the 5' cap for superior, sustained translation efficiency, ensuring robust protein yield in your applications.